Gilead (GILD) Sciences Stock | Another Reason To Invest

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences is a major player in the biotech space. With a strong hold on the hepatitis C and HIV markets, there’s already plenty of reasons for investors to get excited about the stock. However, yesterday, we learned of a new reason! Gilead Sciences has entered into an agreement to … Read more

Gilead Sciences (GILD) Stock Presents A Great Buying Opportunity

Gilead Sciences, Inc. (NASDAQ: GILD) Following last week’s positive earnings report, Gilead Sciences had a great couple of days in the market. However, the stock is down today and in a big way. While some may be looking at this as tremendously bad news, I see the exact opposite. In my opinion, GILD is doing … Read more

Gilead Sciences (GILD) | AbbVie (ABBV) | What Hep C Patients & Investors Need To Know!

Gilead Sciences, Inc. (NASDAQ: GILD) If you’re a Gilead Sciences follower, patient, or investor, you know what they do. The company is currently the leader in the treatment of hepatitis C. The company’s treatments Harvoni and Sovaldi have incredibly high cure rates, low side effects, and the patient needs to take less medication overall than … Read more

Gilead Sciences (GILD) Stock Climbs On Great Earnings

Gilead Sciences, Inc. (NASDAQ: GILD) As expected, Gilead Sciences reported it’s quarterly earnings report yesterday after the bell. Also meeting my expectations, the company did far better in the first quarter than most analysts expected it to do. So, today we’ll take a look at the earnings report for the quarter, chat about how the … Read more

Gilead Sciences (GILD) | Earnings Should Be A Hit!

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences is expected to release its earnings report today after the bell. So naturally, curiosity strikes and I’ve decided to take a look at what we can expect to see. Here are a few things to keep in mind before the earnings release… GILD HCV Earnings Shouldn’t Be A … Read more

AbbVie (ABBV) Sends A Troubling Message To Gilead Sciences (GILD)

Gilead Sciences, Inc. (NASDAQ: GILD) If you follow biotech stocks, you know the name Gilead Sciences. The bottom line is that this is a massive company that controls both the hepatitis C and HIV treatment spaces. However, they’ve received a troubling message relatively recently… AbbVie Inc (NYSE: ABBV) AbbVie is another pharmaceutical giant. While they’re … Read more

April Earnings To Watch | ABBV | GILD | PFE | MRK

April is more than half way over. However, the most exciting part of the month for many is soon to come! As we move into earnings season, big names in health care are getting set to release their reports. Below are a few earnings reports that I’ll be watching closely and what I expect to … Read more

Gilead Sciences (GILD) Stock Holders…Get Ready For Big Gains!

Gilead Sciences, Inc. (NASDAQ: GILD) If you follow my writing, you know that one of my favorite seasons is upon us once again. It’s earnings report season and GILD will be releasing theirs very soon! When it comes to biotech, there are few stocks that are more interesting to me than Gilead Sciences; and I’m … Read more

Gilead Sciences (GILD) Isn’t Scared Of AbbVie (ABBV) | Neither Are Investors

Gilead Sciences, Inc. (NASDAQ: GILD) For quite some time now, Gilead Sciences has dominated the hepatitis C treatment arena; and for good reason. In the past, treatment of hepatitis C lasted 48 weeks and included a wide variety of vaccines. Sadly enough, there was no where near a 100% success rate in treatment. However, Sovaldi … Read more

Is Merck & Co. A Real Threat To Gilead Sciences & AbbVie Inc?

Gilead Sciences, Inc. (NASDAQ: GILD) | AbbVie Inc (NYSE: ABBV) Gilead Sciences and AbbVie Inc play a major role in the Hepatitis C Virus treatment market. The combination of Sovaldi, Harvoni (GILD) and Viekira (ABBV) is not only incredibly effective in treating the virus, the combination is the market leader around the world. Considering the … Read more